Triple-negative breast cancer (TNBC), a subgroup that lacks expression ... genes Breast cancers occurring in patients with germline BRCA1 mutations are often triple negative and basal like ...

Mutations in BRCA1 and BRCA2 substantially increase ... million Americans suffer from diabetes or pre-diabetes. Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer ...

Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.

The firm will test LP-184 as a monotherapy and in combination with a PARP inhibitor in patients who have DNA damage repair gene mutations.

Tumor-negative breast cancers misclassified as ... Adjuvant trastuzumab has significantly improved the prognosis of breast cancer patients both in terms of disease-free survival and overall ...

Among patients with triple-negative breast cancer, the Naples prognostic score predicted survival outcomes more accurately ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...

Women diagnosed with breast cancer who carry particular BRCA1 and BRCA2 genetic variants are offered surgery to remove the ...

WITTMANN, Ariz. — A Valley mother battling a rare form of breast cancer is empowering women to get regular health screenings.

Gene mutations BRCA1 and BRCA2 are considered high ... Got *** cancer diagnosis of triple negative breast cancer, um, and that quickly it was maybe 18 months later and she died Christmas Eve.

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.